ArticleJPRAS open2026
Venous thromboembolism prophylaxis regimen for patients undergoing deep inferior epigastric perforator flap breast reconstruction.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients undergoing deep inferior epigastric perforator (DIEP) flap breast reconstruction are at increased risk for venous thromboembolism (VTE) due to prolonged operative times, cancer-associated hypercoagulability, and postoperative immobility. Despite this risk, consensus is limited regarding standardized prophylaxis regimens for this population. We assessed VTE incidence in patients undergoing DIEP flap breast reconstruction after implementing a standardized, multimodal VTE prophylaxis regimen. Methods: We retrospectively reviewed patients who underwent DIEP flap breast reconstruction at our institution between October 2021 and July 2024. Patients were subjected to a standardized VTE prophylaxis regimen including preoperative education and subcutaneous heparin injection, intraoperative efficiency techniques, and a postoperative protocol consisting of early ambulation, sequential compression devices, compressive garments, and a 2-week course of enoxaparin sodium. Patient characteristics, operative details, and VTE outcomes were analyzed. Results: In a cohort of 110 patients, 187 DIEP flap reconstruction procedures were performed by one surgeon. Mean patient age was 49.3 years, and mean body mass index was 29.7. The VTE rate directly attributable to DIEP flap reconstruction was 0%. One VTE event occurred-an upper extremity deep vein thrombosis (DVT) 119 days postoperatively that was associated with intravenous access during a revision procedure. No lower-extremity DVTs or pulmonary embolisms were reported. Conclusions: Implementation of a standardized, comprehensive VTE prophylaxis regimen encompassing preoperative, intraoperative, and postoperative measures can result in a remarkably low VTE rate in patients undergoing DIEP flap breast reconstruction. This safe, effective regimen may eliminate the need for risk-based pharmacologic stratification tools such as the Caprini model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.